Flexion Therapeutics Inc
FLXNDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001419600
Flexion Therapeutics Inc was delisted in 2021; its insiders filed their last Form 4 on Nov 23, 2021; 145 institutions reported holding it in 13F filings for Q3 2021, worth $230.5M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Flexion Therapeutics Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Flexion Therapeutics Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Newtyn Management, LLC | 10% Owner | 0Indirect | Nov 23, 2021 | 0 |
| Driscoll Frederick W | Chief Financial Officer | 0 | Nov 19, 2021 | 0 |
| Colella Samuel D | Director | 0Indirect | Nov 19, 2021 | 0 |
| Milinazzo Alan | Director | 0 | Nov 19, 2021 | 0 |
| Merrifield C Ann | Director | 0 | Nov 19, 2021 | 0 |
| Mahaffy Patrick J | Director | 0 | Nov 19, 2021 | 0 |
| Canute Scott A | Director | 0 | Nov 19, 2021 | 0 |
| Wentworth Kerry | Chief Regulatory Officer | 0Indirect | Nov 19, 2021 | 0 |
| Stejbach Mark | Director | 0 | Nov 19, 2021 | 0 |
| Lukatch Heath | Director | 0 | Nov 19, 2021 | 0 |
| Clayman Michael D. | President and CEO | 0Indirect | Nov 19, 2021 | 0 |
| Levine Mark S. | General Counsel | 0 | Nov 19, 2021 | 0 |
| Andrews William T. | Chief Medical Officer | 0 | Nov 19, 2021 | 0 |
| Koppikar Utpal | Director | – | Nov 19, 2021 | 0 |
| Willwerth Christina | Chief Strategy Officer | 0 | Nov 19, 2021 | 0 |
| Layman Melissa | Chief Commercial Officer | 0 | Nov 19, 2021 | 0 |
| Kwo Elizabeth | Director | 0 | Nov 19, 2021 | 0 |
| Muzikant Adam | Chief Business Officer | 0 | Nov 19, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 20, 2021 (view filing) | Jul 19 | 1 day | Willwerth ChristinaChief Strategy Officer | SSale | −3.94K | $6.45 | −$25.4K | −2.7%141.2K after | |
| Jul 20, 2021 (view filing) | Jul 19 | 1 day | Wentworth KerryChief Regulatory Officer | SSale | −3.94K | $6.45 | −$25.4K | −2.7%140.4K after | |
| Jul 20, 2021 (view filing) | Jul 19 | 1 day | Muzikant AdamChief Business Officer | SSale | −1.87K | $6.45 | −$12.1K | −1.8%103.7K after | |
| Jul 20, 2021 (view filing) | Jul 19 | 1 day | Levine Mark S.General Counsel | SSale | −3.94K | $6.45 | −$25.4K | −2.9%133.5K after |